Pharmaceutical company Elan has forecast a ⁈150m-⁈175m full-year before-tax loss, excluding revenues from its suspended MS drug Tysabri..Revenue for the first three months of the year was $134.3m (⁈106m), ahead of analysts' forecasts of $127.1m (⁈100m).
Ireland On-Line
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
California Diagnostics Maker Cited for Adulterated Devices
The agency found a lack of evidence that customers used the devices solely for forensic and R&D purposes, as required by their instructions for use.
Glenmark’s Abiraterone Acetate Tablets Approved
The approval brings Glenmark’s portfolio to 162 products authorized for distribution in the U.S., with 46 ANDA’s pending approval, the company said.
FDAnews Drug Daily Bulletin
ELAN REAFFIRMS TYSABRI COMMITMENT
May 5, 2006
